97
Participants
Start Date
April 11, 2019
Primary Completion Date
November 22, 2025
Study Completion Date
February 2, 2026
Cemiplimab
Each patient will receive intralesional injections of cemiplimab every week (QW), or at less frequent dosing into the lesion at the assigned dose level for 3-12 weeks prior to scheduled surgery
Peter MacCallum Cancer Centre, Melbourne
Alfred Health, Melbourne
Princess Alexandra Hospital, Brisbane
Fremantle Dermatology, Fremantle
Rochester Dermatologic Surgery, P.C., Victor
Inova Schar Cancer Institute, Fairfax
Duke Cancer Center, Durham
MetroDerm, Atlanta
Dermatology Associates of the Palm Beaches, Delray Beach
The University of Texas MD Anderson Cancer Center, Houston
Medical Dermatology Specialists, Phoenix
TCR Medical Corporation, San Diego
Northeast Dermatology Associates, Beverly
Radboud University Medical Center, Nijmegen
Maastricht University Medical Center, Maastricht
The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam
University of Groningen, University Medical Centre Groningen, Groningen
Erasmus MC, Rotterdam
Regeneron Pharmaceuticals
INDUSTRY